Researchers at the University of California San Diego have uncovered a key mechanism underlying the treatment resistance of ...

There are several types of BRAF mutation that can occur, but the most common type is V600E. Adenocarcinoma refers to the location where lung cancer starts. In this case, it refers to the outer ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.

V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer acquired through its $11.4 billion takeover of Array Biopharma in 2019 – was previously approved in combination ...

A novel tool for rapidly identifying the genetic "fingerprints" of cancer cells may enable future surgeons to more accurately ...

"The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward ...

Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E. The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY ...